Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
Top Cited Papers
Open Access
- 15 November 2008
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 112 (10) , 4017-4023
- https://doi.org/10.1182/blood-2008-05-159624
Abstract
Minimal residual disease (MRD) assessment is standard in many hematologic malignancies but is considered investigational in multiple myeloma (MM). WeKeywords
This publication has 41 references indexed in Scilit:
- Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose TherapyJournal of Clinical Oncology, 2008
- Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: A retrospective studyLeukemia & Lymphoma, 2008
- Conventional diagnostics in multiple myelomaEuropean Journal Of Cancer, 2006
- International uniform response criteria for multiple myelomaLeukemia, 2006
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005
- Minimal residual disease monitoring in multiple myelomaBest Practice & Research Clinical Haematology, 2002
- Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcomeBlood, 2002
- Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhoodThe Lancet, 1998
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998
- Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemiaThe Lancet, 1992